EVLO
Healthcare BiotechnologyEvelo Biosciences, Inc.
$0.00
+0.00 +0.00% today Live
Price History
Not enough data
| Date | Price |
|---|---|
| Oct 5, 2026, live at 12:55 PM ET | 0.00 |
Key Stats
Market Cap
1,898.284
Avg Volume
33
EPS
-$3.14
52W High
$0.00
52W Low
$0.00
Div. Yield
0.0%
Valuation
Forward P/E
-0.00
P/B Ratio
-0.00
EV/EBITDA
-0.24
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Assets
(83.2%)
Liquidity & Leverage
Current Ratio
0.48
Quick Ratio
0.43
Total Cash
17.26M
Total Debt
33.95M
About
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.